RECCE® 327 I.V.

RECCE® 327 (R327) was developed beginning with the end in mind, being entirely synthesised to capture and enhance unique mechanisms of action, able to overcome deadly viral and bacterial infections, including the full suite of ESKAPE pathogens, even in their multi-drug resistant forms.


Urinary tract infections (UTIs) are a common type of infection, accounting for 10-20% of infections treated in a primary care or hospital setting and roughly 30-40% of anti-infective use in hospitals. UTIs occur when bacteria enter the urethra and infect the urinary tract. Patients typically report initial symptoms such as a feeling of full bladder after urinating and pain during urination and visit their primary care doctor for treatment. Although UTIs are most often effectively treated with antibiotics, a 2019 study revealed that nearly 90% of the most common bacteria causing UTIs are resistant to one drug, and up to 80% are resistant to two.
A urine culture can confirm the presence of bacteria in the urine and the infection, sometimes indicating the best antibiotic to start treatment. Most patients, roughly 60%, will begin to feel better within a week with the first course of antibiotics. However, several rounds of treatment may be needed for those with recurrent or complicated UTIs, or the infection can spread into the bloodstream, leading to sepsis. Sepsis that results from UTIs is referred to as urosepsis. In general, 25% of sepsis cases originate from the urogenital tract.

UTI Cases and Fatalities by Geographical Area



400 million


deaths in 2019



of the women in the USA will develop a UTI at some point in their lifetime



4 million

patients acquired healthcare- associated UTIs annually





UTI Patient Journey

About RECCE® 327

RECCE® 327 (R327) is a synthetic anti-infective developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including the full suite of ESKAPE pathogens, even in their superbug forms. R327’s novel mechanism of action (MOA) is designed to safely enter the body, identify and treat an infection, and exit – with the potential to overcome antimicrobial resistance.
R327, as an IV therapy, is being studied in a broad range of bacterial infections.
Preclinical studies have demonstrated R327’s ability to rapidly and irreversibly shut down bacterial cellular energy ATP production, disrupting important functions within the bacteria, leading to:
This multi-layered MOA uniquely allows it to kill bacteria and keep on killing with repeated use, a challenge of all existing antibiotics.